Table 3.
Patient details of panel positive in Gastrc cancer patients
| P53 | NY‐ESO‐1 | |||||
|---|---|---|---|---|---|---|
| Positive | ‐ | + | ‐ | + | ||
| Number | 212 (85.5%) | 36 (14.5) | 224 (90.3%) | 24 (9.7) | ||
| Gender | ||||||
| Male (%) | 149 (60.1) | 32 (12.9) | P = .034 | 162 (65.3) | 19 (7.7) | P = .634 |
| Female | 63 (25.4) | 4 (1.6) | 62 (25.0) | 5 (2.0) | ||
| Mean age ± s.d. (y) | 67.3 ± 9.9 | 67.3 ± 10.2 | 67.1 ± 10.5 | 71.1 ± 8.4 | ||
| Age range (y) | 37‐89 | 47‐84 | 37‐89 | 52‐81 | ||
| T‐classification | ||||||
| T1 | 118 (47.6) | 19 (7.7) | P = .939 | 130 (52.4) | 7 (2.8) | P = .043 |
| T2 | 28 (11.3) | 4 (1.6) | 29 (11.7) | 3 (1.2) | ||
| T3 | 27 (10.9) | 4 (1.6) | 24 (9.7) | 7 (2.8) | ||
| T4 | 39 (15.7) | 9 (3.6) | 41 (4.8) | 7 (2.8) | ||
| Lymph node metastasis | ||||||
| Positive | 61 (24.6) | 18 (7.3) | P = .011 | 68 (27.4) | 11 (4.4) | P = .122 |
| Negative | 151 (60.9) | 18 (7.3) | 156 (48.0) | 13 (2.4) | ||
| Distant metastasis | ||||||
| Positive | 40 (16.1) | 7 (2.8) | P = .882 | 36 (14.5) | 11 (4.4) | P < .001 |
| Negative | 172 (69.4) | 29 (11.7) | 188 (75.8) | 13 (5.3) | ||
| Peritoneal dissemination | ||||||
| Positive | 25 (10.1) | 6 (2.4) | P = .586 | 25 (10.1) | 6 (2.4) | P = .104 |
| Negative | 187 (75.4) | 30 (12.1) | 199 (80.2) | 18 (7.3) | ||
| TNM stage | ||||||
| I | 137 (55.2) | 18 (7.3) | P = .412 | 146 (58.9) | 9 (3.6) | P = .019 |
| II | 7 (2.8) | 1 (0.4) | 8 (3.2) | 0 (0.0) | ||
| III | 21 (8.5) | 7 (2.8) | 26 (10.5) | 2 (0.8) | ||
| IV | 47 (19.0) | 10 (4.0) | 45 (11.3) | 12 (4.8) | ||
| CEA | ||||||
| Positive | 32 (12.9) | 11 (4.4) | P = .023 | 35 (14.1) | 8 (3.2) | P = .058 |
| Negative | 180 (72.6) | 25 (10.0) | 189 (76.2) | 16 (6.5) | ||
| CA19‐9 | ||||||
| Positive | 28 (11.3) | 7 (2.8) | P = .462 | 29 (11.7) | 6 (2.4) | P = .192 |
| Negative | 184 (74.2) | 29 (11.7) | 195 (78.6) | 18 (7.3) | ||
Abbreviations: CEA, carcinoembryonic antigen; s.d., standard deviation.
Factors with statistically significant differences are indicated by bold P‐values.